Santhera, Ikris Sign Agreement for Distribution of AGAMREE in India

Santhera Pharmaceuticals has signed an exclusive agreement with Ikris Pharma Network (Ikris) to manage the distribution of AGAMREE (vamorolone) in India, for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older.

The agreement has a 5-year term, and Santhera will receive a percentage of net sales, in line with previous distribution agreements. Sales are expected to begin in Q4 2025 on a named patient basis.

Dario Eklund, CEO of Santhera, said: “We are pleased to partner with Ikris Pharma Network in India, which is part of our wider strategy to increase global access to AGAMREE for patients with DMD. Ikris has been actively working in the area of DMD and their expertise and dedication to ensuring rare disease drugs reach patients make them an ideal partner in the region.”

Praveen Sikri, Founder & CEO of Ikris Pharma Network, said: “This collaboration with Santhera aligns with our focus on addressing unmet medical needs in the rare disease community. We look forward to leveraging our distribution network to help DMD patients in India access this life-changing treatment.”